I'm interested in

  • All types
  • General AML
  • DNA Methylation (DNMT3A)

    DNA Methylation (DNMT3A)

    DNA Methylation (DNMT3A)
    • DNMT3A
  • DNA Demethylation (IDH1/2)

    DNA Demethylation (IDH1/2)

    DNA Demethylation (IDH1/2)
    • IDH1/2
    • TET2
  • Activated Signaling (FLT3)

    Activated Signaling (FLT3)

    Activated Signaling (FLT3)
    • FLT3
  • Myeloid Transcription Factors (RUNX1)

    Myeloid Transcription Factors (RUNX1)

    Myeloid Transcription Factors (RUNX1)
    • RUNX1
  • Tumor Suppressor / Multifactorial (TP53, NPM1)

    Tumor Suppressor / Multifactorial (TP53, NPM1)

    Tumor Suppressor / Multifactorial (TP53, NPM1)
    • TP53
    • NPM1
  • Chromatin Regulation
  • Spliceosome
  • Cohesin

Interested in specific type?

Filter what you see here

  • Medical Information
  • Licences
  • Trials
  • About
  • Sign Up

SHARE

General AML

Prof. Eduardo M. Rego | EHA 2017 | Management of APL in Latin America

Eduardo Rego , Jun 27, 2017 , Expert Opinion

L: English
Watch Portuguese version

EHA 22nd Congress - June 22-25, 2017, Madrid, Spain. 

 

Our partners

Our supporters

Platinum
Silver
Bronze
Bronze
Bronze
Bronze
Bronze

Our contributors

  • Terms and conditions
  • Cookie policy
  • Newsletter

© 2018 AML Global Portal

All content on this site is intended for healthcare professionals only.